Air Liquide is renewing its support for the European Federation of Allergy and Airways Diseases Patients Associations (EFA), a year after the signature of a partnership agreement.
The Brussels-based organisation unites national associations of patients suffering from respiratory diseases and aims to increase awareness of the needs of these patients at European level.
The EFA has 22 countries represented, with up to 500,000 members.
Air Liquide supports the efforts initiated by the EFA to inform and increase awareness of European public opinion and public authorities regarding chronic obstructive pulmonary disease (COPD).
Considered an under-diagnosed condition, COPD is a major public health issue. The prevalence of COPD varies in European countries from 4-10% of the adult population. The World Health Organisation predicts that by 2030 COPD will be the third cause of mortality worldwide.
Air Liquide also supports EFA actions aimed at facilitating travel for patients on oxygen therapy, by for example harmonising air transport conditions for patients on oxygen, which would make access to their treatment easier.